Association of blood-based neurodegenerative biomarkers with cognitive functioning and dementia in India (LASI-DAD) and the United States (HRS) - Takeaways - MDSpire

Association of blood-based neurodegenerative biomarkers with cognitive functioning and dementia in India (LASI-DAD) and the United States (HRS)

  • By

  • Jung Ki Kim

  • Masroor Anwar

  • Abhishek Gupta

  • Bharat Thyagarajan

  • Peifeng Hu

  • Jessica D Faul

  • David R Weir

  • Kenneth M Langa

  • Jinkook Lee

  • Sharmistha Dey

  • Eileen M Crimmins

  • August 21, 2025

  • 0 min

Share

  • 1

    The study analyzes blood-based neurodegenerative biomarkers and their associations with cognitive functioning in older adults from India and the United States.

  • 2

    Higher levels of GFAP and NfL correlate with worse cognitive function and increased dementia likelihood in both populations studied.

  • 3

    The Aβ42/Aβ40 ratio shows differing associations with cognitive functioning between the two countries, indicating potential cultural or environmental influences.

  • 4

    pTau181 was generally not linked to cognitive functioning in either population, suggesting limited utility as a predictive marker.

  • 5

    Cross-national research on neurodegenerative biomarkers can enhance understanding of cognitive decline and dementia across diverse populations.

Original Source(s)

Association of blood-based neurodegenerative biomarkers with cognitive functioning and dementia in India (LASI-DAD) and the United States (HRS)

  • by Jung Ki Kim, Masroor Anwar, Abhishek Gupta, Bharat Thyagarajan, Peifeng Hu, Jessica D Faul, David R Weir, Kenneth M Langa, Jinkook Lee, Sharmistha Dey, Eileen M Crimmins

  • August 21, 2025

Related Content

Association between circulating biomarkers of one-carbon metabolism and glymphatic system function in cognitive decline of Alzheimer’s disease

Late-life difficult-to-treat depression and dementia subtypes: a naturalistic cohort study using electronic health records

Inner retinal layer thickness reflects plasma biomarkers in preclinical Alzheimer’s disease